Clinical trials are warranted, which evaluate the ability of COX-2 inhibitors and NSAIDs as the sole therapeutic in order to determine their chemopreventive value in human subjects with both NMSCs and melanoma. The gene discussed is PTGS2; the disease is melanoma.